Eledon Pharmaceuticals Inc. has announced that it will host a Research and Development Day in New York City on July 9, 2025. The event will focus on Eledon's lead investigational candidate, tegoprubart, particularly its clinical development in organ and cell transplantation. The event will feature members of Eledon's executive team and several leading experts in transplantation, who will discuss topics such as the ongoing Phase 2 BESTOW trial and unmet needs in solid organ transplantation. Additional sessions will address the evolution of clinical endpoints and strategic opportunities in islet cell transplantation and xenotransplantation. The program will conclude with a live Q&A session. Presentation materials and a live webcast of the event will be accessible on the company's website. Results from the studies will be presented during the event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.